

2022 年

英文

Yamada M, Ishikawa T, Iwasa T, Oishi H, Osuka S, Oka K, Ono S, Ono M, Orisaka M, Kanasaki H, Kawano Y, Kawamura K, Kishi H, Kimura F, Kuroda S, Kuwahara A, Kobayashi H, Komiya A, Saito H, Sato K, Sato S, Shiraishi K, Shirasawa H, Suzuki T, Takai Y, Takae S, Takahashi T, Takiuchi T, Tachibana M, Tamura I, Tamura H, Jwa SC, Baba T, Harada M, Hirata T, Fukui A, Fukuda Y, Fukuhara S, Maruyama T, Yumura Y, Yoshino O, Hirota Y, Tsujimura A, Kuji N, Osuga Y.

Guidelines for Reproductive Medicine in Japan.

Reproductive Medicine and Biology 2022;21(1):e12483

Tamada S, Kondoh C, Matsubara N, Mizuno R, Kimura G, Anai S, Tomita Y, Oyama M, Masumori N, Kojima T, Matsumoto H, Chen M, Li M, Matsuda K, Tanaka Y, Rini BI, Uemura H. Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study.

International Journal of Clinical Oncology. 2022; 27(1):154-164.

Nishiyama N, Kobayashi T, Narita S, Hidaka Y, Ito K, Maruyama S, Mukai S, Tsutsumi M, Miki J, Okuno T, Yoshio Y, Matsumoto H, Shimazui T, Segawa T, Karashima T, Masui K, Fukuta F, Tashiro K, Imai K, Suekane S, Nagasawa S, Higashi S, Fukui T, Kojima T, Morita S, Ogawa O, Nishiyama H, Kitamura H; Japan Urological Oncology Group. Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching.

Journal of Geriatric Oncology. 2022; 13(1):88-93.

Tomita Y, Yamamoto Y, Tsuchiya N, Kanayama H, Eto M, Miyake H, Powles T, Yoshida M, Koide Y, Umeyama Y, di Pietro A, Uemura H. Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis.

International Journal of Clinical Oncology. 2022; 27(2):383-395.

Mizokami A, Nishimoto K, Matsuyama H, Ichikawa T, Takahashi S, Shiina H, Hashine K, Sugiyama Y, Kamiyama M, Enokida H, Nakajima K. Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate

Cancer in Clinical Practice.

Anticancer Research. 2022; 42(3):1465-1475.

Kazama H, Kawaguchi O, Seto T, Suzuki K, Matsuyama H, Matsubara N, Tajima Y, Fukao T. Comprehensive analysis of the associations between clinical factors and outcomes by machine learning, using post marketing surveillance data of cabazitaxel in patients with castration-resistant prostate cancer.

BMC Cancer. 2022; 22(1):470.

Kamijima T, Yaegashi H, Mizokami A, Nakajima K, Matsuyama H, Ichikawa T, Nishimoto K, Takahashi S, Shiina H, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A, Enokida H. Efficacy of Androgen Receptor-targeted Drugs After Prostate Cancer Recurrence With Bone Metastases: PROSTAT-BSI Sub-analysis.

Anticancer Research. 2022; 42(6):3099-3108.

Miyake M, Iida K, Nishimura N, Inoue T, Matsumoto H, Matsuyama H, Fujiwara Y, Komura K, Inamoto T, Azuma H, Yasumoto H, Shiina H, Yonemori M, Enokida H, Nakagawa M, Fukuhara H, Inoue K, Yoshida T, Kinoshita H, Matsuda T, Fujii T, Fujimoto K; Nishinohon Uro-oncology Extensive Collaboration Group. Site-specific Risk Stratification Models for Postoperative Recurrence and Survival Prediction in Patients with Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy: Better Stratification for Adjuvant Therapy.

European Urology Open Science. 2022; 41:95-104.

Nagumo Y, Onozawa M, Kojima T, Terada N, Shiota M, Mitsuzuka K, Yasumoto H, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Saito T, Yokomizo A, Kohei N, Tabata KI, Takahashi A, Sugimoto M, Kitamura H, Kamoto T, Nishiyama H; Japanese Urological Oncology Group (JUOG). Efficacy of combined androgen blockade therapy in patients with metastatic hormone-sensitive prostate cancer stratified by tumor burden.

International Journal of Urology. 2022; 29(5):398-405.

Shiota M, Takamatsu D, Kimura T, Tashiro K, Matsui Y, Tomida R, Saito R, Tsutsumi M, Yokomizo A, Yamamoto Y, Edamura K, Miyake M, Morizane S, Yoshino T, Matsukawa A, Narita S, Matsumoto R, Kasahara T, Hashimoto K, Matsumoto H, Kato M, Akamatsu S,

Joraku A, Kato M, Yamaguchi T, Saito T, Kaneko T, Takahashi A, Kato T, Sakamoto S, Enokida H, Kanno H, Terada N, Suekane S, Nishiyama N, Eto M, Kitamura H; Japanese Urological Oncology Group. Radiotherapy plus androgen deprivation therapy for prostate-specific antigen persistence in lymph node-positive prostate cancer. *Cancer Science*. 2022; 113(7):2386-2396.

Tohi Y, Kato T, Fukuhara H, Kobayashi K, Ohira S, Ikeda K, Daizumoto K, Katayama S, Shimizu R, Nishimura K, Nagami T, Hayashida Y, Hiramata H, Takamoto A, Dainichi T, Sugimoto M; Chu-shikoku Japan Urological Consortium. Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan Urological Consortium. *International Journal of Clinical Oncology*. 2022; 27(8):1348-1355.

Uemura H, Matsumoto R, Mizokami A, Miyake H, Uemura H, Matsuyama H, Nakamura K, Saito K, Kawakita M, Takeshita H, Koroki Y, Ono S, Murota M, Ito M, Kamoto T, Fujimoto K. Treatment strategies and outcomes in a long-term registry study of patients with high-risk metastatic hormone-naïve prostate cancer in Japan: An interim analysis of the J-ROCK study. *International Journal of Urology*. 2022; 29(9):1061-1070.

Koshiro N, Nakajima K, Oyama M, Kaneko G, Takahashi S, Matsuyama H, Shiina H, Ichikawa T, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A, Mizokami A; PROSTAT-BSI Investigators. Predictive factors for the effectiveness of novel androgen receptor axis-targeted agents in patients with metastatic prostate cancer. *International Journal of Urology*. 2022; 29(12):1477-1487.

和文

堀江重郎, 天野俊康, 石井智弘, 井手久満, 伊藤直樹, 岩月正一郎, 上芝元, 大山力, 小川純人, 蔭山和則, 方波見卓行, 川戸佳, 菅野潤子, 功刀浩, 重原一慶, 周東孝浩, 白石晃司, 白川智也, 鈴木和浩, 高岡正和, 高橋裕, 竹石恭知, 立花修, 田邊真紀人, 辻村晃, 鳥居俊, 西岡宏, 長谷川奉延, 畠山真吾, 濱島崇, 濱野逸人, 福井道明, 福岡秀規, 松井克之, 松下一仁, 溝上敦, 村元啓仁, 八木弘子, 安井孝周, 柳瀬敏彦, 義久精臣, 男性の性腺機能低下症ガイドライン作成委員会, 一般社団法人日本内分泌学会, 一般社団法人日本メンズヘルス医学会. 男性の性腺機

能低下症ガイドライン 2022.

日本内分泌学会雑誌. 2022; 8(Suppl)1-140.

三宅 秀明, 井上 貴博, 白石 晃司, 木村 高弘, 田中 一, 堀田 記世彦. 査読委員の確保と教育.

日本泌尿器科学会雑誌. 2022; 113(Suppl) 150-156.

寺本 昌司, 増田 裕, 稲垣 誠, 白石 晃司, 稲元 輝生, 東 治人. Microdissection-TESE で精子採取不可能であったが,左停留精巣固定術後に射出精子が出現し,ICSI により 2 児の妊娠成立した 1 例.

西日本泌尿器科. 2022; 85(2)63-66.